InsiderPulse
Dashboard

BEAM

Beam Therapeutics Inc.

Health CareRussell 2000

Beam Therapeutics Inc. insider trading

Beam Therapeutics Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Cambridge, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent BEAM insider transactions

6 insiders traded BEAM on the open market between Feb 24, 2026 and Jul 27, 2026 — 16 sales worth $15.9M, of which 14 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$15.9M

14 of 16 on a 10b5-1 plan

Net
−$15.9M
Insiders
6

Open-market purchases (code P) and sales (code S) from Beam Therapeutics Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every BEAM Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

BEAM insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded BEAM on the open market: 0 purchases and 49 sales worth $25.7M, 45 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 30 sales ($18.6M), by 7 insiders.

QuarterBoughtSold
Q2 2026—−$11.5M7 sales · 5 on a plan
Q1 2026—−$4.7M13 sales · all on a plan
Q4 2025—−$1.5M7 sales · 6 on a plan
Q3 2025—−$1M3 sales · 2 on a plan
Q2 2025—−$1.4M6 sales · all on a plan
Q1 2025—−$1.4M6 sales · all on a plan
Q4 2024—−$2.7M4 sales · all on a plan
Q3 2024—−$1.5M3 sales · all on a plan
Largest sale
−$8.9M of BEAM by Fmr LLC (10% Owner) on Jun 26, 2026.

Open-market transactions through Jun 30, 2026most recent first

  • Evans John M.10b5-1

    CEO · Director

    −$569K

    Mar 31, 2026

    25,000 sh · $22.76

  • Evans John M.10b5-1

    CEO · Director

    −$559.3K

    Mar 30, 2026

    25,000 sh · $22.37

  • Ciaramella Giuseppe10b5-1

    President

    −$1.1M

    Feb 24, 2026

    35,000 sh · $32.00

  • Evans John M.10b5-1

    CEO · Director

    −$624.6K

    Jan 30, 2026

    22,094 sh · $28.27

  • Evans John M.10b5-1

    CEO · Director

    −$84.3K

    Jan 30, 2026

    2,906 sh · $29.00

  • Evans John M.10b5-1

    CEO · Director

    −$476.8K

    Jan 29, 2026

    16,333 sh · $29.19

  • Evans John M.10b5-1

    CEO · Director

    −$257.8K

    Jan 29, 2026

    8,667 sh · $29.74

  • Cavanagh Bethany J10b5-1

    SVP, Finance and Treasurer

    −$216.9K

    Jan 22, 2026

    6,198 sh · $35.00

  • Bellon Christine10b5-1

    Chief Legal Officer

    −$46.6K

    Jan 22, 2026

    1,371 sh · $34.00

  • Cavanagh Bethany J10b5-1

    SVP, Finance and Treasurer

    −$91.4K

    Jan 20, 2026

    3,034 sh · $30.12

  • Bellon Christine10b5-1

    Chief Legal Officer

    −$554.1K

    Jan 15, 2026

    15,959 sh · $34.72

  • Bellon Christine10b5-1

    Chief Legal Officer

    −$71K

    Jan 15, 2026

    2,111 sh · $33.62

  • Bellon Christine10b5-1

    Chief Legal Officer

    −$19.8K

    Jan 15, 2026

    559 sh · $35.40

  • Emany Sravan Kumar10b5-1

    Chief Financial Officer

    −$170.6K

    Dec 31, 2025

    6,294 sh · $27.10

  • Bellon Christine10b5-1

    Chief Legal Officer

    −$34K

    Dec 31, 2025

    1,254 sh · $27.10

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Beam Therapeutics Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Cambridge, MA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001745999

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought BEAM

What the stock actually did in the 90 days following each open-market purchase

Don't check BEAM — let it ping you

Get told the moment an insider moves on BEAM

Pro watches Beam Therapeutics Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add BEAM to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track BEAM on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read BEAM insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

RXRXTWSTPACBARWRIONSAXSMKRYSRAREFOLDACADPTCTMEDP
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are BEAM insiders buying or selling?
Between Feb 24, 2026 and Jul 27, 2026, 6 Beam Therapeutics Inc. insiders made no open-market purchases and 16 sales worth $15.9M, a net sale of $15.9M. 14 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much BEAM stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 7 Beam Therapeutics Inc. insiders made no open-market purchases and 49 sales worth $25.7M. 45 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 30 sales ($18.6M). The largest sale was Fmr LLC selling $8.9M on Jun 26, 2026.
What was the largest recent BEAM insider trade?
Fmr LLC (10% Owner) sold $8.9M of BEAM stock on Jun 26, 2026 at about $35.26 a share.
When did an insider last buy BEAM shares?
No open-market purchase by a Beam Therapeutics Inc. insider appears in the filings from Feb 24, 2026 to Jul 27, 2026 — every recorded open-market transaction in that period was a sale.
Where does BEAM insider trading data come from?
From the Form 4 filings Beam Therapeutics Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.